Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Liver Disease
55%
Fibrosis
40%
Liver Transplantation
36%
Hepatocyte
31%
Liver Cirrhosis
30%
Liver Fibrosis
25%
Cell Therapy
22%
Liver Injury
20%
Non-Alcoholic Fatty Liver Disease
19%
Stem Cell
18%
Diseases
18%
Mesenchymal Stem Cell
17%
Systematic Review
17%
Hematopoietic Cell
15%
Meta-Analysis
13%
Fatty Liver
13%
FibroScan
11%
Chronic Liver Disease
11%
Placebo
10%
Hepatocellular Carcinoma
9%
Liver Biopsy
9%
Diabetes
9%
Clinical Trial
9%
Liver Graft
8%
Maturity Onset Diabetes of the Young
8%
Steatosis
8%
Prevalence
8%
Arm
8%
Steatohepatitis
7%
COVID-19
7%
Immunity
7%
Randomized Controlled Trial
7%
Alcohol Liver Disease
7%
Insulin Resistance
7%
Primary Health Care
7%
Liraglutide
7%
Liver Regeneration
7%
Stem Cell Therapy
7%
Infusion
7%
Population
6%
Transient Elastography
6%
Diagnostic Accuracy
6%
End Stage Liver Disease
6%
Aspartate Aminotransferase
6%
Drug Therapy
6%
Biopsy Technique
6%
Bioartificial Liver
6%
Inflammatory Disorder
5%
Granulocyte Colony Stimulating Factor
5%
Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
84%
Nonalcoholic Steatohepatitis
53%
Liver Disease
45%
Liver Transplantation
38%
Liver
36%
Cirrhosis
25%
Fibrosis
21%
Liver Fibrosis
19%
Mesenchymal Stromal Cells
18%
Cell Therapy
16%
Stem Cells
16%
Liver Injury
15%
Hepatocytes
14%
Advanced Fibrosis
13%
Chronic Liver Disease
13%
Mesenchymal Stem Cells
12%
Hepatocellular Carcinoma
11%
Liver Biopsy
11%
Fibroscan
11%
Liver Stiffness
11%
Obesity
10%
Bone Marrow Cells
10%
Phase II Trial
9%
Type 2 Diabetes Mellitus (T2DM)
9%
Hematopoietic Stem Cells
8%
Clinical Trials
8%
Hepatocyte-like Cells
8%
Granulocyte Colony-stimulating Factor (G-CSF)
8%
Steatosis
8%
Glucagon-like
8%
Murine Model
8%
Primary Care
7%
Insulin Resistance
7%
Alcoholic Hepatitis
7%
Placebo
7%
Liver Cirrhosis
7%
Paracetamol
7%
Liraglutide
7%
End-stage Liver Disease
7%
Human Liver
7%
Stem Cell Therapy
7%
Fatty Liver Disease
6%
Meta-analysis
6%
Liver Regeneration
6%
Human Mesenchymal Stem Cells (hMSCs)
6%
Diagnostic Accuracy
6%
Vibration-controlled Transient Elastography
6%
Metabolic-associated Fatty Liver Disease (MAFLD)
6%
Fibrosis Stage
6%
Alcohol
6%